Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Published . Updated .
Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reduction
Directly affected
- NDAQ Nasdaq
Named in this report.
Indirectly affected
- CNTB CONNECT BIOPHARMA HLDGS LTD
GA selected CNTB as a RELATED security because its canonical security name directly matches this event's themes: biopharma, connect. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met…
Source: Nasdaq Markets
The price since 5 Oct 2026: Connect Biopharma Holdings (CNTB) versus the S&P 500
Since the first closing price after “Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures,” Connect Biopharma Holdings (CNTB) is -0.03%. The S&P 500 fund (SPY) is -1.60% over the same days, a +1.57% difference versus the market.
Who gains and who loses around Connect Biopharma Holdings (CNTB)
Companies carried with this story
- CNTB Connect Biopharma Holdings
For “Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures,” Connect Biopharma Holdings (CNTB) is linked, with no stored direction, medium confidence. Reason on file: GA selected CNTB as a RELATED security because its canonical security name directly matches this event's themes: biopharma, connect. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Connect Biopharma Holdings (CNTB)
On 5 Oct 2026, “Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures” is the story that connects Connect Biopharma Holdings (CNTB) to this story.
For Connect Biopharma Holdings (CNTB), the reason on file says GA selected CNTB as a RELATED security because its canonical security name directly matches this event's themes: biopharma, connect. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Connect Biopharma Holdings (CNTB) price range
CNTB traded between 0.85 and 1.88 across 20 sessions. The latest close on file is 0.91.
What the saved facts support for Connect Biopharma Holdings (CNTB)
14 out of 100
“Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.